Abstract
This laboratory has reported previously that Δ9-tetrahydrocannabinol (Δ9-THC) and cannabinol (CBN) robustly elevate intracellular calcium ([Ca2+]i) in resting human and murine T cells, whereas CP55,940 [5-(1,1-dimethylheptyl)-2-(5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)phenol], a high-affinity ligand for CB1 and CB2, does not. In light of our previous studies, the objective of the present investigation was to examine the ability of various cannabinoid compounds to elevate [Ca2+]i in the CB2 receptor-expressing human peripheral blood acute lymphoid leukemia T cell line and the dependence of structural similarity to Δ9-THC therein. The present studies demonstrate that CBN and HU-210 [(6aR,10aR)-3-(1,1-dimethylbutyl)-6a,7,10,10a-tetrahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol], both tricyclic and in that respect structurally similar to Δ9-THC, elevate [Ca2+]i. The [Ca2+]i elevation elicited by both CBN and HU-210 was attenuated upon removal of extracellular calcium and upon pretreatment with SK&F96365 [1-[β-[3-(4-methoxyphenyl)propoxy]-4-methoxyphenethyl]-1H-imidazole], an inhibitor of receptor-operated cation channels. In addition, pretreatment with either CB1 or CB2 receptor antagonists attenuated the CBN- and HU-210-mediated [Ca2+]i elevation. Further investigation of the dependence of Δ9-THC, CBN, and HU-210 on cannabinoid receptors using splenocytes from wild-type and CB1-/-/CB2-/- mice showed that the [Ca2+]i elevation elicited by all three tricyclic cannabinoids was independent of CB1 and CB2. Moreover, both the CB1 and CB2 receptor antagonists attenuated that rise in [Ca2+]i elicited by the tricyclic cannabinoids in the wild-type and CB1-/-/CB2-/- mouse splenocytes. Taken together, the present results demonstrate that classic tricyclic cannabinoids with structural similarity to Δ9-THC elicit a robust influx of calcium in T cells putatively through receptor-operated cation channels in a manner sensitive to the cannabinoid receptor antagonists, but independent of the CB1 and CB2 receptors.
Footnotes
-
This work was supported by funds from National Institute of Drug Abuse Grants DA07908, DA020402, and DA016828.
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.105.100503.
-
ABBREVIATIONS: Δ9-THC, Δ9-tetrahydrocannabinol; SR1, SR141716A, N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorphenyl)-4-methyl-H-pyrazole-3-carboxyamide hydrochloride; SR2, SR144528, N-[(1S)-endo-1,3,3-trimethyl bicyclo[2,2,1]heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide; CP55,940, 5-(1,1-dimethylheptyl)-2-(5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)phenol; HPB-ALL, human peripheral blood acute lymphoid leukemia; CBN, cannabinol; CBD, cannabidiol; AA, arachidonic acid; WIN 55,212-2, (R)-(+)-[2,3-dihydro-5-methyl-3[(4-morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl) methanone mesylate salt; JWH-133, (6aR,10aR)-3-(1,1-dimethylbutyl)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; HU-210, (6aR,10aR)-3-(1,1-dimethylbutyl)-6a,7,10,10a-tetrahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol; AM, acetoxymethyl ester; VH, vehicle; DMSO, dimethyl sulfoxide; ROC, receptor-operated cation; SKF, SK&F96365, 1-[β-[3-(4-methoxyphenyl)propoxy]-4-methoxyphenethyl]-1H-imidazole; SPLC, splenocyte; WT, wild-type.
- Received December 22, 2005.
- Accepted January 23, 2006.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
